Monday, March 15, 2021


Time stands still at historic Cairo watch shop


A wall clock at The Papazian's, Cairo -

VIDEO


Copyright © africanews
By Rédaction Africanews
and AFP Last updated: 14/03 -

EGYPT
Time seems to have stood still at Papazian's, an Armenian Egyptian watchmaker whose almost 120-year-old Cairo shop has withstood the decades, surviving political upheavals and urban transformations.

Sheltered from the hustle and bustle of the capital's unforgiving traffic and surrounded by street vendors in Attaba Square, the unassuming shop housed under the arcades of an old Haussmannian building is a time capsule of Cairo's rich cosmopolitan history.

It is a rare museum-like site where old clocks, watches and timepieces are meticulously repaired.


"I have spare parts from my grandfather's days," Ashod Papazian, the current 64-year-old owner who inherited the family business, told AFP.

The shopfront with patinated wooden frames boasts an impressive array of pocket watches and wrist models with ageing bracelets, as well as yellowed advertisements of the vaunted watchmaker.

At the turn of the 19th century, Egypt had become a popular destination for Armenians who specialised in delicate manual crafts such as jewell ery-making, along with a thriving European community that included Italians, Greeks, Jews and French citizens.

The Armenian community, estimated to have numbered between 40,000 and 60,000 before Egypt's 1952 anti-monarchy revolution, mostly living in Cairo and Alexandria, has dwindled to only around a few thousand now.

In his small office surrounded by a quaint mess of archives, books and clocks of all kinds, Ashod is the keeper of precious memories.

Two black-and-white portraits hang behind his armchair: of his grandfather Nerses, known as Francis, the founder of the store, and of Ashod's own father Sarkis.

Under the more than century- old counters, dozens of wooden drawers contain spare parts of almost every imaginable brand of watch.

Antique comtoise pendulum chimes or cuckoo clocks -- some from the 19th century -- occupy every inch of available wall space.

They belong to customers who have entrusted him to repair them or owned by the watch enthusiast himself -- who refuses to part with his rarest timepieces.

- The Rich and Famous -

In 1893, Nerses Papazian, drafted into the Ottoman army, escaped by jumping on a boat without knowing his final destination, his grandson said. He ended up in Alexandria on Egypt's Mediterranean coast.

Ten years later, he opened the watch shop in Cairo that carries his name on the storefront to this day.

Building a reputation, he attracted several stars from the golden age of Egyptian cinema such as Youssef Wahbi, Fouad el-Mohandes and Abdelmoneim Ibrahim as customers.

Papazian also said the family of King Farouk, Egypt's last monarch, called his father Sarkis to the royal palace to have their pick from a wide array of watches.

Later when Egypt's Free Officers movement led by Gamal Abdel Nasser, the country's first president, overthrew the monarchy, the newly-established republic's elite also adopted Papazian.

"After the revolution there were (army) officers who dropped by, they were friends with my dad. They loved watches," he said.

Papazian's retains many loyal customers, but there are no succession plans on the cards for his two sons in their 20s.

"Most of the clients have become friends. We don't have anyone just passing through here," he explained.

Talaat Farghaly, 71, said he has been frequenting the shop ever since 1965.

The Armenian watchmaker is "very reliable", he said.

"We respectfully call him 'Khawaga' (the foreigner)," said Farghaly, who works in import-export.

Ahmed el-Melegy, 62, a printer, is also an aficionado with more than 35 in his watch collection.

"My passion for clocks began in 1984," he said.

"I often passed Ashod's shop and was fascinated. One day I decided to buy myself a clock for my wedding. Since then I haven't been able to stop," he recalled.
At least six die in factory explosion in Gabes city, Tunisia
Volume 90%
  




















Copyright © africanews

By Rédaction Africanews

Last updated: 14/03 -

TUNISIA

At least six people have died and one was injured in the explosion on Saturday of an asphalt tank in an industrial zone in Gabès, in south-eastern Tunisia.

The explosion, "the causes of which are not yet known", occurred at 9:30 am local (08:30 GMT).

"We made in a first preliminary assessment six dead and one wounded", Moez Triaa, the spokesperson for civil protection said.

Four people died on the spot and the other two after being transported to a hospital in Gabès.

Search operations to find other possible victims are still ongoing, added Mr. Triaa, without being able to give more details.

According to photos published by local media, a huge black smoke covered part of the industrial zone of Gabès.

Panic As Massive Deportation Of Nigerians From Germany Begins Tomorrow

The upcoming charter deportation operation will be the first for this year since the initial plan for January 18 was cancelled owing to the Coronavirus pandemic, SaharaReporters has gathered.

BY SAHARAREPORTERS,
 NEW YORK
MAR 15, 2021

Many Nigerians illegally staying in Germany will leave Frankfurt for Lagos on Tuesday, March 16, 2021, as part of massive deportation plans by the German government, the Network for Critical Migration Consciousness (NfCMC) has announced.

The upcoming charter deportation operation will be the first for this year since the initial plan for January 18 was cancelled owing to the Coronavirus pandemic, SaharaReporters has gathered.

Nigerian activists protesting last year in Dresden at an event organised by the Voice Refugees ForumOsaren Igbinoba

A statement by the NFCMC noted that at a February meeting with the Nigerian Ambassador in Berlin, Ambassador Tugger informed the NGC president-led delegation of his engagement with the Presidential Task Force on Covid-19 to address the situation of deportation and the risk of the Corona pandemic.

He further confirmed the Federal government's position to refuse landing permits for deportation flights based on the collective responsibility to contain the coronavirus's further spread.

Ambassador Tugger's intervention arose from a November 2020 Zoom conference organised by the Nigerian Community (NGC München) with the Nigerian Ambassador as a guest.

Ambassador Tugger was commended for his commitment to interact with Nigerians throughout the online section.

His attention was drawn to the ongoing deportation collaboration, ignoring Germany's position as a major Corona hotspot (Germany exporting Corona to Nigeria) – especially at a time when the country is still trying to cope with the continued economic hardship from the Corona lockdown, bad governance and subsequent incidents like insecurity and insurgency, corruption, religious and ethnic conflicts, #EndSARS #RestructureNigeriaNow revolution etc.

The group urged those who are not too sure of their residential status, otherwise with so-called Duldung Status (Tolerated/Obligated to leave the country), to contact their lawyers or their asylum counselling centres.

"Please be aware that arrest is ongoing based on provisions of the German Foreigners Law which legitimates keeping so-called tolerated persons in deportation custody to guarantee their availability for a planned deportation enforcement flight.

"We would categorically like to draw the attention of persons who are at the moment participating in the German so-called Voluntary Returns Program – a project of the racist "Perspective Heimat Program" meant to coerce asylum seekers to volunteer for their self-deportation.

"Experiences have proven that such persons could be used to fill up spaces in scheduled chartered deportation flights since their passports are in possession of the foreign officers.

"An obvious eyeopener was the December 10, 2020 deportation enforcement. Two young Nigerians, who had trusted and were actively cooperative in the Voluntary Return Program, were brutally deported to Nigeria.

"That deportation incidence exposes more realities of the German Voluntary Returns Program as a farce. Further investigation of the issue has proven that the respective Foreign Officers were receiving routine updates on their active and cooperative engagement in the training courses. A worse scenario is that the respective Foreign Officers were lying even three days before the deportation enforcement. They appeared for the covid-19 test unknowing that this was meant to prepare them for the following deportation flight schedule.

"After the scandalous and inhuman deportation incidence, correspondences with the deportation responsible, authorities confirm the fact that the so-called Voluntary Return program remains only as an offer with no binding legislation to suspend deportation until the successful completion of the Voluntary Returns Preparatory training. Such wasted expenses are borne out of taxpayers funds."

Interested in Advertising?Sponsored Ad
SAHARAREPORTERS, NEW YORK

TRAVEL
NEWS


YOU MAY ALSO LIKE
Italian Firm On Corruption Trial Granted High Level EU Access To Lobby For Fossil Gas, Agency Alleges

A new report from Global Witness, a non-governmental online research agency, reveals alleged attempts to obstruct justice by Eni executives.

BY  SAHARAREPORTERS, NEW YORK
MAR 15, 2021

An Italian energy firm, Eni, has been granted access to push fossil gas at the highest echelons of the EU, despite being on trial for an alleged bribery scheme involving millions of dollars channelled to politicians.

A new report from Global Witness, a non-governmental online research agency, reveals alleged attempts to obstruct justice by Eni executives.



This was contained in a release signed by Senior Communications Adviser, Dominic Kavakeb, obtained by SaharaReporters.

He said later this month, a verdict is expected in the Italian trial where Eni, Shell and senior executives are accused of knowing the $1.1bn they paid in 2011 for a Nigerian offshore oil field (OPL 245), would be used to pay bribes to Nigerian public officials.

According to the report, Eni’s CEO, Claudio Descalzi, who is also individually on trial in the same Italian case met with the EU’s Energy Commissioner in June, 2020.

Despite facing a possible eight-year prison term, Descalzi was granted a meeting with one of the EU’s most senior officials to discuss the role of fossil gas in the future of the EU, amongst other topics.

This follows a meeting with the Commissioner for Internal Markets in September 2018, the very same month public hearings in the corruption trial began.

According to the report, Eni’s in-house lobbyists hold more passes for the European Parliament than any other oil and gas firm. It was also alleged that, the lobbyists have been in 49 meetings with senior EU officials since 2014 — the second most of all Italian companies.

In that time, Eni, and the pro-fossil gas industry groups of which it is a member, have spent up to 100 million Euros lobbying in Europe.

With coal and oil out of vogue in the EU, fossil gas has become a key last stand for fossil fuel companies, with Eni central to the industry’s push.

A presentation, sourced by Global Witness from public records of information requests, delivered by Eni to EU climate officials argued for gas as a “clean and safe partner” for renewables and called for support for the “coal-to-gas switch”.

Gas Campaigner at Global Witness, Barnaby Pace said: “The European Commission has waxed lyrical over its ambitions to fight climate change yet grants unrivalled access to some of the world's biggest polluters. Serious action on the climate will not come about by giving fossil fuel companies access to policy making, particularly those who seem ever willing to ride roughshod over the rules.

“Fossil fuel companies must be prevented from polluting the political process. We don’t ask tobacco companies for advice on quitting smoking, so we shouldn’t be asking those who got rich from oil and gas for climate advice.”

Italian prosecutors also allege that Eni executives arranged kickbacks for themselves as part of the deal. In a separate, fast-tracked Italian trial, two middlemen involved in the deal have already been sentenced to jail terms with the judge in that case ruling that the management of Shell and Eni were “fully aware” that part of their $1.1bn payment for the block “would be used to remunerate Nigerian public officials''.

She further ruled that it was proven that Eni managers planned and possibly received kickbacks from the deal. The conviction has been appealed.

The ruling in the fast-tracked trial does not in any way determine the guilt of defendants in the ongoing trial, though it shows that the allegations against Eni, Shell, Descalzi and others are credible and must be taken seriously. The defendants in the case have all pleaded not guilty and denied wrongdoing.

Allegations of misconduct against Eni do not stop there. Italian prosecutors have alleged that Eni managers ordered surveillance against journalists, prosecutors and possibly even judges.

Descalzi and several other Eni managers are suspects in a related criminal investigation into attempts to interfere in the investigation into the OPL 245 case.

Eni told Global Witness that all the charges and allegations regarding OPL 245 and the alleged conspiracy are unsubstantiated and they have provided all the evidence to the Milan court and judicial authorities to support their case.

Eni also stated that its transition plan “is ambitious, detailed, and wider in scope commitments than our peers and has been welcomed by a number of external experts and commentators” and that it rejects “the allegations and insinuations” regarding the company’s “commitment to the energy transition.” The EU Commission did not respond to an opportunity to comment on the findings and recommendations of the report.

Barnaby Pace said: “From the criminal investigations into Descalzi and Eni you’d be forgiven for thinking this is an organised crime group on trial rather than a global oil and gas firm. Eni managers are accused of interfering in investigations, attempting to bribe a witness, and spying on law enforcement and journalists on top of paying hundreds of millions of dollars in bribes, all to secure oil and gas that cannot be burned if we are to avoid the worst impacts of climate change.”
AFRICA AT THE Grammy Awards 2021: Nigerians Burna Boy and Wizkid win

Copyright © africanewsAndy Kropa/2019 Invision

By Africanews Last updated: 8 hours ago

MUSIC















The 2021 Grammy Awards was historic this year and not just because artists performed on stage to no audience due to coronavirus restrictions.

The show dubbed as "music's biggest night" was monumental for African artists.

Nigeria Afrobeats stars Burna Boy and Wizkid both won awards.



Burna Boy, whose real name is Damini Ogulu, won the Best Global Music Album category with his Twice as Tall.

He said: "Africa is here! we are here! You hear me? This is something fantastic for all Africans of my generation, all over the world, and this should be a lesson for all Africans, whatever you are, wherever you are, you can achieve it."

His nomination said the album was "a masterclass in the vibe and hustle that have made Burna Boy an international musical force".

"[He] continues to torch limitations, seamlessly blending styles and genres and fearlessly fuelling the fire heating the melting pot of pop, Afrobeat, dancehall, reggae and more," it said.

His album features artists such as Stormzy, Youssou Ndour, Naughty By Nature, and Chris Martin of Coldplay.

Burna Boy lost out to Angelique Kidjo in 2020 for the same category.



The video which saw Wizkid win was described as "a feast for the fashion-forward and a celebration of Black and brown female beauty everywhere".

Wizkid's music video was for his song with Beyoncé; Brown Skin Girl, from Lion King: The Gift album.

The video which saw Wizkid win was described as "a feast for the fashion-forward and a celebration of Black and brown female beauty everywhere".

Beyonce's daughter Blue Ivy was also a winner on the song.

Social justice


The awards show in Los Angeles also made social justice a key theme.

South African host Trevor Noah introduced told viewers they can see the names of nearly 1,000 people in the music industry who died last year at Grammys.com.

H.E.R.'s "I Can't Breathe"-- a response to the death of George Floyd-- won song of the year.

"I've never been so proud to be an artist. We wrote this song over FaceTime, and I didn't imagine that my fear and my pain would turn into impact and it would possibly turn into change," she said as she accepted the award.

Brittany Howard, backed up by Chris Martin on piano, ended the tribute with a stirring version of the Broadway standard "You'll Never Walk Alone."

It was also a historic night for women Beyonce won her 28th Grammy and became the most decorated woman in Grammy history.

Taylor Swift also had a huge night had a historic night, becoming the first female performer to win album of the year three times.

Burna Boy, Wizkid, Seven Others Of Nigerian Descent Who Have Won The Grammy Awards

Burna Boy bagged the much-coveted Grammy award in the ‘Best Global Album’ category for his ‘TWICE AS TALL’ album.

BY SAHARAREPORTERS, NEW YORK
MAR  15, 2021

Nigerian music stars, Damini Ebunoluwa Ogulu, better known as Burna Boy and Ayodeji Balogun, better known as Wizkid, on Sunday night, won their first ever Grammy Awards.

Burna Boy bagged the much-coveted Grammy award in the ‘Best Global Album’ category for his ‘TWICE AS TALL’ album.

Burna Boy

He was nominated alongside Tuareg Desert rock group, Tinariwen; NYC afrobeat outfit, Antibalas; Brazilian-American, Bebel Gilberto; and British-Indian sitar player, Anoushka Shankar.

This is the second consecutive time Burna Boy has been nominated for the Grammys.

His previous album, ‘African Giant’ was nominated at the 62nd Grammy Awards for ‘Best World Music Album’, but the award went to Beninoise singer, Angélique Kidjo, who dedicated the award to Burna Boy and said he was leading the pack of young Africans who will shake up the global music space.

Burnaboy is the first winner of the recently renamed category, formerly known as Best World Music Album.

Wizkid, on the other hand, won a Grammy for the Best Music Video’ for his role in ‘Brown Skin Girl’, Beyonce’s 2019 hit song. The Best Music Video award is given to the artist, video director, and video producer.

Their video bested fellow nominees Future with Drake, Anderson.Paak, Harry Styles, and Woodkid.

Here are seven Nigerians who have won the awards in the past:

Helen Folasade Adu (Sade Adu)


Sade Adu, British-Nigerian singer, who turned 62 on 16 January, 2021 has won the award.

She made history as the first Nigerian singer to win a Grammy.

Born on January 16, 1959, in Ibadan, Nigeria, Sade was raised in London. She had been nominated for the Grammy awards nine times and won four times.

She won her first Grammy in 1986 in the Best New Artist category. She also won the Best R&B Performance by a duo or group with vocals in 1994 for the song, “No Ordinary Love.”

Sade also won another Grammy in 2002 in the category of the Best Pop Vocal Album, with the song “Lovers Rock,” while in 2011, she won the Best R&B Performance by a group with vocals for “Soldier of Love.”

Sikiru Adepoju


69 year-old Sikiru Adepoju is a percussionist and recording artist from Nigeria, primarily in the genres of traditional African music and world music. He plays a variety of instruments and styles.

Born in Eruwa, Oyo State, Adepoju was a member of Ebenezer Obey’s Inter Reformers Band until he left for the US in 1985. In the US, the ‘drummer boy’ joined O. J. Ekemode’s Nigerian All-Stars, and three months later met Babatunde Olatunji.

He became an integral part of Olatunji’s Drums of Passion, and through Olatunji met Grateful Dead drummer Mickey Hart.

He was part of Mickey Hart’s group Planet Drum, whose title album won the Grammy Award for Best Contemporary World Music Album in 1991, the first year there was a Grammy in that category.

He was also part of Mickey Hart’s latest group Global Drum Project, whose title album won the Grammy Award for Best Contemporary World Music Album at the 51st annual Grammy Awards in Los Angeles 8 February 2009.

Olusegun Olumide Adeola Samuel (Seal)

Born Henry Olusegun Adeola Samuel in 1963, he is better known by his professional name– Seal. He is a British-Nigerian musician, singer and songwriter best known for his 1994 hit song, “Kiss from a Rose.” He has 14 Grammy nominations to his name and has won four. His song, “Kiss From A Rose” earned him three Grammy awards in 1996 and in 2011 he nabbed his fourth “Imagine”. He holds one of the highest numbers of Grammy awards by a Nigerian.

Lekan Babalola


Born in 1960, Lekan Babalola is a Nigerian jazz percussionist and musician who started playing the conga at an early age. He has seven albums to his name and two Grammy awards. He began his professional career after joining a band called Samba Samba Band and later New York City-based Art Blakey’s Jazz Messengers band, where he perfected playing the Bongo drums and performing jazz music. In 2006, he became Nigeria’s first Grammy Award winner for his work on Ali Farka Touré‘s In the Heart of the Moon which he was credited in three tracks. He also won a second Grammy in 2009 for his work on Cassandra Wilson‘s 2008 album titled Loverly.

Hakeem Seriki


Nigerian-American Hakeem Seriki, better known by his stage name Chamillionaire is a rapper, entrepreneur, and investor from Houston, Texas. He was born November 28, 1979 in Washington D.C to a Muslim Nigerian father and an African-American Christian mother. He moved to Houston, Texas at the age of four

He began his career independently with local releases in 2002, including the collaborative album Get Ya Mind Correct with fellow Houston rapper and childhood friend Paul Wall. He signed to Universal Records in 2005 and released The Sound of Revenge under Universal. It included hit singles “Turn It Up” featuring Lil’ Flip and the number-one, Grammy-winning hit “Ridin'” featuring Krayzie Bone of Bone Thugs-n-Harmony. The song won the Grammy in 2007 for Best Rap Performance by a Duo or Group. It was also nominated for Best Rap song.

Chamillionaire is also known for his most anticipated Mixtape Messiah series, which ran from 2004 until 2009.

Kevin Olusola







Ethiopia's Tigray: 70% of health facilities 'vandalised and looted'


Arsema Berha, 9-years-old, is pushed by her mother as she
 sits in a wheelchair at the Ayder Referral Hospital in the
 Tigray capital Mekele on February 25, 2021 -
© africanews EDUARDO SOTERAS/AFP or licensors


By Africanews Last updated: 3 hours ago

ETHIOPIA

Almost 70% of health facilities in Ethiopia's war-hit northern region of Tigray have been looted and more than 30% had been damaged, a report by Medecins Sans Frontieres said.

The medical charity said health facilities were "deliberately" attacked to make them "non-functional", which has caused a "devastating" impact on the population, MSF said.

It visited 106 health facilities between mid-December 2020 and early March 2021.

The conflict erupted on November 4, 2020, after Prime Minister Abiy Ahmed ordered an offensive to oust the region's former ruling party.

There are still reports of fighting despite Ahmed declaring victory at the end of November.

Before the conflict, Tigray had one of the best health systems in Ethiopia, according to MSF.



The charity reported a hospital in the town of Semema had been set on fire and a delivery room at Sebeya was destroyed after the facility was hit by a rocket.


The charity also said in rural areas of Tigray women died in childbirth because they were unable to get to a hospital due to the lack of ambulances, rampant insecurity on the roads and a night-time curfew.

'Protect health facilities'


“The health system needs to be restored as soon as possible,” said MSF's general director Oliver Behn,

“Health facilities need to be rehabilitated and receive more supplies and ambulances, and staff need to receive salaries and the opportunity to work in a safe environment.

"Most importantly, all armed groups in this conflict need to respect and protect health facilities and medical staff.”

Hundreds of civilians have been killed in the conflict and tens of thousands have been displaced.

Only 13% of the 106 facilities that teams from MSF visited between December and early March were operating normally.

In early March, the United Nations High Commissioner for Human Rights Michelle Bachelet called for an objective and independent investigation into Tigray, after having "corroborated serious violations" likely to constitute as "war crimes and crimes against humanity".
French uranium mining company set for closure in Niger


Copyright © africanews
PIERRE VERDY/AFP
By Rédaction Africanews 


French nuclear group Orano’s COMINAK uranium mine in Niger has announced it will shut down by the end of March 2021 due to the depletion of its reserves, the mine’s board of directors announced last week.

The company has been mining uranium in the region for over 40 years.

Cominak will render over 600 employees jobless but plans are underway to compensate for their social plan.

The company has announced that it will pay its employees between $36,000 and $109,000 as part of the compensation program.

The company has also vowed to restore the area to its original state and will plant trees after a complete demolition.

The French group had also cited high operational costs amidst scarcity of uranium and low prices of the ore on the market.

Prices have fallen in the face of oversupply in the wake of the signing of COP21, the Paris climate agreement

BOSTON
‘That doesn’t work for us’: Congressman Stephen Lynch blasts the MBTA over recent service cuts and furloughs

"Now they're going to take the billion dollars and lay people off? I don't think so."



Rep. Stephen Lynch speaks at a press conference in The Great Hall of Faneuil Hall on Monday. –Pat Greenhouse / The Boston Globe







By Christopher Gavin, Boston.com Staff
March 15, 2021 

Congressman Stephen Lynch, speaking on behalf of the state’s congressional delegation Monday morning, slammed the MBTA for rolling out a wave of service cuts to its core system as Massachusetts receives $1 billion for its transportation agencies under the latest federal COVID-19 relief plan.

“It is incongruous with with our intent … that an agency would take federal support from the taxpayer and then cut services to those same taxpayers,” Lynch said during a press conference highlighting the $1.9 trillion American Rescue Plan passed by lawmakers last week. “That doesn’t work for us.”

On Sunday, the MBTA began controversial service cuts to subway and bus service in an attempt to save money lost by the significant drop in ridership during the pandemic. The move follows cuts to commuter rail and ferry service put in place earlier this year. Officials say they intend to restore service as ridership rebounds.

The loss in revenue also prompted Keolis Commuter Services, the company that operates the commuter rail, to indefinitely furlough 40 conductors and assistant conductors — approximately 9 percent of the system’s conductor workforce.

“They’re going to take the billion dollars and lay people off? I don’t think so,” Lynch said.

The MBTA received over $1 billion in federal relief funding over the past year — cash that helped cover losses in fare revenue. In the 2019 fiscal year, the agency brought in almost $700 million. By the time the current 2021 fiscal year ends in late June, the MBTA expects it will have collected less than $200 million.

Agency officials have said they are saving some of the previously allotted relief funds to put toward the 2022 fiscal year, as well as budget reallocations and other cost-saving efforts. (This year’s service cuts are expected to save about $21 million.)

They expect a gradual return to pre-2020 ridership to take several years, with the most optimistic scenario seeing a return of 89 percent of 2019 levels by 2026. Even so, a four-year budget deficit would total almost $1.8 billion by that point.

The projections notably do not account for the latest relief cash from federal lawmakers. MBTA officials said earlier this month they did not expect to receive specific numbers until several weeks after the massive relief package passed.

“With ridership remaining at less than a third of pre-pandemic levels, the MBTA continues to monitor work and travel patterns and match service to ridership, while increasing service for the most transit-critical communities,” MBTA spokesman Joe Pesaturo told Boston.com in a statement Monday in response to Lynch’s remarks. “As it plans ahead for the long-term budget impacts of the pandemic, the T will responsibly spend federal stimulus dollars and monitor ridership and make adjustments as necessary.”

Lynch, while detailing parts of the latest relief plan, said the state’s entire congressional delegation is opposed to the service cuts and furloughs. He told reporters his fellow lawmakers are “furious about this.”

“The whole idea here is to move the country and the state and cities and towns back to a more normal pattern of life,” Lynch said.

The South Boston Democrat called on Gov. Charlie Baker and MBTA leaders to “come back to the table” with legislators.

“Let’s get everybody on the same page because there are important decisions that have to be made,” Lynch said. “There are important fights that need to be fought, and we need to be together if we’re going to be successful on behalf of the people in Massachusetts.”

According to Lynch, Massachusetts is slated to receive about $8 billion in federal aid under the American Rescue Plan, with an additional, approximately $435 million allotment for Boston alone.

In total, the legislation provides $50 billion in aid to small businesses, $130 billion to help K-12 schools reopen, $27.5 billion in rental assistance, $10 billion for homeowner assistance, and $20 billion to expand COVID-19 vaccine distribution, among other allocations.

“We want to get America back to work and that will require all aspects of our society to re-emerge,” Lynch said.

RELATED LINKS


WORST WEEK EVER A DIGEST
AstraZeneca to reduce EU Covid vaccine deliveries following production problems


Issued on: 15/03/2021 - 

A picture shows empty phials of the AstraZeneca Covid-19 vaccine at a vaccination center at the University of Western Brittany on March 12, 2021 in Brest, western France. 
© Fred Panneau, AFP

Text by: NEWS WIRES

The European Union is facing further shortfalls in its coronavirus inoculation programme after pharmaceutical giant AstraZeneca said production problems and export restrictions would reduce planned deliveries of its vaccine.

The Anglo/Swedish firm's image has already taken a hit with several countries suspending the rollout of its vaccine over blood clot fears, even as the World Health Organization said there was no reason to stop using it.

It is just the latest blow for the AstraZeneca vaccine, which is the cheapest vaccine aimed at fighting back against a pandemic that has claimed more than 2.6 million lives worldwide.


Germany has already reported adverse effects due to the delay, the state of Thuringia cancelling appointments and suspending a pilot project for general practitioners to administer the vaccine.

>> How the EU’s Covid-19 vaccine rollout became an ‘advert for Brexit’

The head of the country's disease control agency Robert Koch Institute, Lothar Wieler, meanwhile warned that "the third wave has already started in Germany".

Despite the worrying signs, thousands joined protests in German cities on Saturday against anti-Covid measures.

France on a 'razor's edge', says PM

French Prime Minister Jean Castex said his government still expected to exceed its target of 10 million vaccinated by April 15, though he said some labs were not respecting delivery deadlines.

Castex defended the use of the AstraZeneca vaccine despite precautions taken by other nations.

>> New strain of Covid-19 tripled infections despite UK lockdown

"I would not allow myself to send poison to my fellow citizens," he said during a visit to a vaccination centre.

He also did not rule out a new lockdown in the Ile-de-France region, which is home to the capital Paris, saying he was ready to take "additional measures" if necessary.

"We are on a razor's edge," he told Le Monde newspaper, as the first three intensive care patients were moved from Ile-de-France to nearby regions on Saturday to relieve the pressure on overwhelmed hospitals in the capital.

Hospital in Jordan runs out of oxygen


The United States, the country hit hardest by the pandemic, has ramped up its vaccination programme after a shaky start.

The Centers for Disease Control and Prevention said 100 million doses had been administered so far, just less than a third of the total given worldwide so far.

Tunisia and Ethiopia both launched vaccination campaigns on Saturday, with Ethiopian officials flagging an alarming rise in cases.

There was outrage in Jordan after at least seven Covid-19 patients died on Saturday when a hospital ran out of oxygen.

"I have submitted my resignation to the prime minister," said health minister Nazir Obeidat, adding that he took "full moral responsibility" for what happened.

WHO: No link between AstraZeneca jab, blood clotting

Several countries suspended the use of AstraZeneca's vaccine this week, with Norway reporting an "unexpected death from a brain haemorrhage" after receiving the shot.

Norwegian officials added on Saturday that the country had "received several adverse event reports about younger vaccinated people with bleeding under the skin" after getting the shot.

It also said it had received "three more reports of severe cases of blood clots or brain haemorrhages in younger people who have received the AstraZeneca vaccine".

The World Health Organization, which said its vaccines advisory committee was examining the safety data coming in, has stressed that no causal link has been established between the AstraZeneca vaccine and blood clotting.

"Yes, we should continue using the AstraZeneca vaccine," WHO spokeswoman Margaret Harris said Friday, stressing that any concerns over safety must be investigated.

AstraZeneca insisted its jab was safe, adding there was "no evidence" of higher blood clot risks.

Italy and Austria have banned the use of jabs from separate batches of AstraZeneca, and Thailand and Bulgaria said this week they would delay their rollout.

Austria, the Czech Republic, Slovenia, Bulgaria and Latvia meanwhile called for EU talks to discuss "huge disparities" in vaccine distribution, according to a letter published on Saturday.

"If this system were to carry on, it would continue creating and exacerbating huge disparities among member states by this summer, whereby some would be able to reach herd immunity in a few weeks while others would lag far behind," the letter said.

Italy on Friday announced tough new restrictions, with schools, restaurants, shops and museums ordered to close across most regions of Italy, including Rome and Milan from next week.

(AFP)

Germany, Italy, France suspend AstraZeneca shots amid safety fears, disrupting EU vaccinations

By Thomas EscrittStephanie Nebehay
3/15/2021

BERLIN/GENEVA (Reuters) - Germany, France and Italy said on Monday they would suspend AstraZeneca COVID-19 shots after several countries reported possible serious side-effects, but the World Health Organization

Teacher, Rene Kirstein, receives his first dose of AstraZeneca's COVID-19 vaccine from nurse Susanne Kugel, amid the spread of the coronavirus disease (COVID-19) in Grevesmuehlen, Germany, March 5, 2021. REUTERS/Fabian Bimmer

(WHO) said there was no proven link and people should not panic.

Still, the decision by the European Union’s three biggest countries to put inoculations with the AstraZeneca shot on hold threw the already struggling vaccination campaign in the 27-nation EU into disarray.

Denmark and Norway stopped giving the shot last week after reporting isolated cases of bleeding, blood clots and a low platelet count. Iceland and Bulgaria followed suit and Ireland and the Netherlands announced suspensions on Sunday.

Spain will stop using the vaccine for at least 15 days, Cadena Ser radio reported, citing unnamed sources.

The top WHO scientist reiterated on Monday that there have been no documented deaths linked to COVID-19 vaccines.

“We do not want people to panic,” Soumya Swaminathan said on a virtual media briefing, adding there has been no association, so far, pinpointed between so-called “thromboembolic events” reported in some countries and COVID-19 shots.

The moves by some of Europe’s largest and most populous countries will deepen concerns about the slow rollout of vaccines in the region, which has been plagued by shortages due to problems producing vaccines, including AstraZeneca’s.

Germany warned last week it was facing a third wave of infections, Italy is intensifying lockdowns and hospitals in the Paris region are close to being overloaded.

German Health Minister Jens Spahn said that although the risk of blood clots was low, it could not be ruled out.

“This is a professional decision, not a political one,” Spahn said, adding he was following a recommendation of the Paul Ehrlich Institute, Germany’s vaccine regulator.

France said it was suspending the vaccine’s use pending an assessment by the EU medicine regulator due on Tuesday. Italy said its halt was a “precautionary and temporary measure” pending the regulator’s ruling.

Austria and Spain have stopped using particular batches and prosecutors in the northern Italian region of Piedmont earlier seized 393,600 doses following the death of a man hours after he was vaccinated. It was the second region to do so after Sicily, where two people had died shortly after having their shots.

The WHO appealed to countries not to suspend vaccinations against a disease that has caused more than 2.7 million deaths worldwide. WHO chief Tedros Adhanom Ghebreyesus said systems were in place to protect public health.

“This does not necessarily mean these events are linked to COVID-19 vaccination, but it’s routine practice to investigate them, and it shows that the surveillance system works and that effective controls are in place,” Tedros said during a virtual media briefing in Geneva.


RELATED COVERAGE
EU regulator to meet on Thursday to discuss AstraZeneca vaccine

He said an advisory committee meeting on AstraZeneca would be held on Tuesday.

The United Kingdom said it had no concerns, while Poland said it thought the benefits outweighed any risks.

The EMA has said that as of March 10, a total of 30 cases of blood clotting had been reported among close to 5 million people vaccinated with the AstraZeneca shot in the European Economic Area, which links 30 European countries.

Michael Head, a senior research fellow in global health at the University of Southampton, said the decisions by France, Germany and others looked baffling.

“The data we have suggests that numbers of adverse events related to blood clots are the same (and possibly, in fact lower) in vaccinated groups compared to unvaccinated populations,” he said, adding that halting a vaccination programme had consequences.

“This results in delays in protecting people, and the potential for increased vaccine hesitancy, as a result of people who have seen the headlines and understandably become concerned. There are no signs yet of any data that really justify these decisions.”

Italian medicine agency Aifa’s general director, Nicola Magrini, told a radio station that several European countries preferred to suspend the vaccine “in the presence of some very recent and very few cases of adverse events” in women and young people.

“...Those who have already had the vaccine can and must remain safe,” she said. “I feel like saying the vaccine is safe, even having reviewed all the data.”

‘UNUSUAL’ SYMPTOMS

AstraZeneca’s shot was among the first and cheapest to be developed and launched at volume since the coronavirus was first identified in central China at the end of 2019, and is set to be the mainstay of vaccination programmes in much of the developing world.

Thailand announced plans on Monday to go ahead with the Anglo-Swedish firm’s shot after suspending its use on Friday, but Indonesia said it would wait for the WHO to report.

The WHO said its advisory panel was reviewing reports related to the shot and would release its findings as soon as possible. But it said it was unlikely to change its recommendations, issued last month, for widespread use, including in countries where the South African variant of the virus may reduce its efficacy.

The EMA has also said there was no indication the events were caused by the vaccination and that the number of reported blood clots was no higher than seen in the general population.

The handful of reported side-effects in Europe have upset vaccination programmes already stumbling over slow rollouts and vaccine scepticism in some countries.

The Netherlands said on Monday it had seen 10 cases of possible noteworthy adverse side-effects from the AstraZeneca shot, hours after putting its vaccination programme on hold following reports of potential side-effects in other countries.

Denmark reported “highly unusual” symptoms in a 60-year-old citizen who died from a blood clot after receiving the vaccine, the same phrase used on Saturday by Norway about three people under the age of 50 it said were being treated in hospital.

“It was an unusual course of illness around the death that made the Danish Medicines Agency react,” the agency said in a statement late on Sunday.

One of the three health workers hospitalised in Norway after receiving the AstraZeneca shot had died, health authorities said on Monday, but there was no evidence the vaccine was the cause.

AstraZeneca said earlier it had conducted a review covering more than 17 million people vaccinated in the European Union and the UK which had shown no evidence of an increased risk of blood clots.

Long-awaited results from AstraZeneca 30,000-person U.S. vaccine trial are currently being reviewed by independent monitors to determine whether the shot is safe and effective, a top U.S. official said on Monday.


Reporting by Panarat Thepgumpanat in BANKOK and Andreas Rinke and Paul Carrel in BERLIN, Angelo Amante in ROME, Christian Lowe in PARIS, Toby Sterling in AMSTERDAM, Jacob Gronholt-Pedersen in COPENHAGEN, Kate Kelland in LONDON, Emilio Parodi in MILAN, Nathan Allen in MADRID, Emma Farge in GENEVA and Stanley Widianto in JAKARTA; writing by Philippa Fletcher; editing by Nick Macfie and Mark Heinrich


WHO gives statement on safety of the Astra Zeneca vaccine after some countries stop using it

Coronavirus vaccine: WHO statement on Astra Zeneca jab safety


By Aidan Barlow @ArgusAidan
Crime Reporter

VACCINE LATEST

Suzie Shakespeare, Senior Immunisation Nurse, prepares a dose of Oxford/Astra Zeneca Covid-19 vaccine, during a mass vaccination of members of the public at Robertson House, Stevenage. Picture date: Tuesday February 9, 2021. PA Photo. Photo credit



COUNTRIES should continue to use the AstraZeneca Covid-19 vaccine, the World Health Organisation (WHO) says.

The WHO said there was no indication of a link between the jabs and blood clots.

It comes after Thailand said it will delay use of the AstraZeneca vaccine after several European countries temporarily suspended the jabs following a small number of reports of health problems.

Speaking via videoconference in Geneva, WHO director general Tedros Adhanom Ghebreyesus said: “As countries roll out Covid-19 vaccines, WHO is continuing to keep a close eye on their safety.

“WHO is aware that some countries have suspended the use of AstraZeneca vaccines based on reports of blood clots in some people who have received doses of the vaccine from two batches.

“This measure was taken as a precaution while a full investigation is finalised.

“It’s important to note that the European Medicines Agency has said there is no indication of a link between the vaccine and blood clots and that the vaccine can continue to be used while its investigation is ongoing.”


He said the findings and any change to the organisation’s recommendations following the investigation will be relayed to the public “immediately”.

His comments echoed earlier remarks made by WHO spokesperson Dr Margaret Harris, who described the vaccine as “excellent”.

Yong Poovorawan, an adviser to Thailand’s vaccination programme, said the delay, pending an investigation into the cause of reported side-effects, will not have a big impact on the rollout.

It came as AstraZeneca released a new statement saying there is no evidence of an increased risk of pulmonary embolism or deep vein thrombosis with the vaccine.

It said that, in fact, the occurrence is “significantly lower” in those who have been vaccinated than what would be expected among the general population.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has said there is no evidence to suggest the vaccine causes blood clot problems, and that people should still get their Covid-19 jab when asked to do so.

The European Medicines Agency (EMA) has also backed the jab’s safety and said there have been 30 reports of blood clots among close to five million people given the vaccine across Europe.

It said in a statement: “The position of EMA’s safety committee… is that the vaccine’s benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing.”

On Thursday, Denmark, Norway and Iceland said they were temporarily halting all AstraZeneca vaccinations to investigate reports of blood clots among people who have had the jab.

Italy also followed Austria, Estonia, Latvia, Luxembourg and Lithuania in banning jabs from one particular batch of one million AstraZeneca vaccines, which was sent to 17 countries, after reports of a death.


AstraZeneca said in a statement on Friday: “An analysis of our safety data of more than 10 million records has shown no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in any defined age group, gender, batch or in any particular country with Covid-19 vaccine AstraZeneca.

“In fact, the observed number of these types of events are significantly lower in those vaccinated than what would be expected among the general population.”

Earlier this week, the EMA reported that one person in Austria was diagnosed with blood clots and died 10 days after vaccination, but stressed there is “currently no indication that vaccination has caused these conditions”.

Another person was admitted to hospital with pulmonary embolism (blockage in arteries in the lungs) after being vaccinated.

Dr Phil Bryan, MHRA vaccines safety lead in the UK, said on Thursday: “Blood clots can occur naturally and are not uncommon.

“More than 11 million doses of the Covid-19 AstraZeneca vaccine have now been administered across the UK.

“Reports of blood clots received so far are not greater than the number that would have occurred naturally in the vaccinated population.”

Dr Bryan said the safety of the public always comes first and the issue is being kept under close review, “but available evidence does not confirm that the vaccine is the cause”.

Professor Anthony Harnden, deputy chairman of the Joint Committee on Vaccination and Immunisation, said: “Vaccine safety is critically important.

“Our UK regulator, the MHRA, reviews all reports of adverse events for both vaccines as they are reported.

“The public should have confidence that both vaccines used in the UK vaccination programme are safe and highly effective at preventing severe disease, including the prevention of blood clots caused by Covid.”


Here's Why Countries Are Halting the AstraZeneca Shot, Explained

The European Medicines Agency and the World Health Organization say the data available do not suggest the vaccine caused the clots and that people should continue to be immunized

By Maria Cheng • Published 5 hours ago • Updated 3 hours ago
Karwai Tang | Getty Images
The Oxford-AstraZeneca covid vaccine.


In recent days, countries including Denmark, Ireland, Thailand, Germany, France and Italy have temporarily suspended their use of AstraZeneca's coronavirus vaccine after reports that some people who got a dose developed blood clots, even though there's no evidence that the shot was responsible.

The European Medicines Agency and the World Health Organization say the data available do not suggest the vaccine caused the clots and that people should continue to be immunized. Here's a look at we know — and what we don't.

WHAT HAPPENED?

Denmark was the first country to halt its use of the AstraZeneca COVID-19 vaccine last week after reports of blood clots in some people, including one person who developed multiple clots and died 10 days after receiving at least one dose. Danish health authorities said the suspension would last for at least two weeks while the cases were investigated, even as they noted that “at present, it cannot be concluded whether there is a link between the vaccine and the blood clots.”

Norway, Iceland, Bulgaria, Thailand, and Congo soon followed suit. On Saturday, Norwegian authorities reported that four people under age 50 who had gotten the AstraZeneca vaccine had an unusually low number of blood platelets. That could lead to severe bleeding. On Sunday, Ireland and the Netherlands announced that they, too, were stopping their use of the AstraZeneca vaccine temporarily.

On Monday, Germany, France and Italy also temporarily suspended use of the AstraZeneca vaccine.

Authorities in the Netherlands — like those elsewhere — said their suspension of the AstraZeneca vaccine was strictly precautionary.

“We must always err on the side of caution, which is why it is sensible to press the pause button now as a precaution,” said Hugo de Jonge, the Dutch health minister.

Still, several other countries have stuck with the vaccine.

In response to the suspensions of its vaccine, AstraZeneca said it had carefully reviewed the data on 17 million people who received doses across Europe. It said there was “no evidence of an increased risk” of blood clots in any age group or gender in any country.

IS THERE ANY PROOF THE VACCINE IS RESPONSIBLE?


No. The European Medicines Agency says there is “no indication that vaccination has caused these conditions." The EU regulator said the number of reports of blood clots in people who received the AstraZeneca vaccine was no higher than for those who hadn't gotten the shot.

In Britain, where 11 million doses of the AstraZeneca vaccine have been administered — more than any other country — there have been reports of about 11 people who developed blood clots after getting a shot. None were proven to have been caused by the vaccine.

Some doctors pointed out that since vaccination campaigns started by giving doses to the most vulnerable people, those now being immunized are more likely to already have health problems. Experts say that could make it difficult to determine whether a vaccine shot is responsible.

More Coronavirus News

SO WHY DID THEY STOP VACCINATION?

Any time vaccines are rolled out widely, scientists expect some serious health issues and deaths to be reported — simply because millions of people are receiving the shots and problems would be expected to occur randomly in a group so large. The vast majority of these end up not being connected to the vaccine, but because COVID-19 vaccines are still experimental, scientists must investigate every possibility that the shot could have some unforeseen side effects. The shots are considered experimental because the vaccines were only developed in the last year, so there is no long-term data for any of them.

“People die every day, and we have more than 300 million people globally who have been immunized who will die of other causes,” said Dr. Mariangela Simao, an assistant director-general at WHO.

IS THIS A CONCERN WITH OTHER COVID-19 VACCINES?

The EMA is currently examining whether COVID-19 shots made by Pfizer-BioNTech, Moderna Inc. and AstraZeneca might be causing low levels of blood platelets in some patients, a condition that could lead to bruising and bleeding.


4:04 Yes, It's Safe! Combatting COVID-19 Vaccine Hesitancy in Black and Brown Communities
Here’s Why Countries Are Halting the AstraZeneca Shot, Explained – NECN
Vaccine hesitancy in the Black and brown community is giving many of those in the most vulnerable populations pause before signing up for a COVID-19 vaccine. Physicians Jubril Oyeyemi and David Hayes-Bautista discuss how to combat vaccine fear in those communities.


HAS ASTRAZENECA RUN INTO OTHER TROUBLE?


The vaccine has been approved for use in adults in more than 50 countries and has been proven to be safe and effective in research done in Britain, Brazil and South Africa. But there have been concerns raised about how the vaccine data have been released, and some European leaders, including French President Emmanuel Macron, have questioned the vaccine's effectiveness.

Britain first authorized the vaccine based on partial results that suggested the shots were about 70% effective. But those results were clouded by a manufacturing mistake that led some participants to get just a half dose in their first shot — an error the researchers didn’t immediately acknowledge. When it recommended the vaccine be licensed, the EMA estimated the vaccine's efficacy to be about 60%.

The data on whether the vaccine protected older adults were also incomplete, leading some European countries to initially withhold the shot from older people.

In the U.S., the Food and Drug Administration suspended a study in 30,000 Americans for an unusual six weeks, as frustrated regulators sought information about some possible side effects reported in Britain.

“All the data we have seen about the AstraZeneca vaccine suggests it's very safe and is saving people from dying of COVID," said Dr. Paul Hunter, a professor of medicine at the University of East Anglia. “But this may be more of a perception problem because every time there is a vaccine issue, we hear the name ‘AstraZeneca’ soon after.”

SO WHAT ARE EXPERTS TELLING PEOPLE TO DO?

The WHO and the EMA — as well as regulators in several countries — say people should continue to be immunized and that the risk of getting vaccinated far outweighs any potential harm.

“The safety of the public will always come first," said Britain's drug regulator. “People should still go and get their COVID-19 vaccine when asked to do so.”

 you are here: science media centre > roundups for journalists > expert reaction to reports that ireland has suspended the use of the oxford-astrazeneca vaccine

Expert reaction to reports that Ireland has suspended the use of the Oxford-AstraZeneca vaccine

There have been reports that the use of the Oxford-AstraZeneca COVID-19 vaccine has been suspended in the Republic of Ireland following reports of blood clotting events in Norway.

 

Dr Peter English, Retired Consultant in Communicable Disease Control, Former Editor of Vaccines in Practice Magazine, Immediate past Chair of the BMA Public Health Medicine Committee, said:

“When a vaccine is administered to millions of people, it is inevitable that some adverse events – that would have happened anyway – will happen shortly after vaccination. When deciding whether the events are a coincidence, or caused by the vaccine, you have to consider biological plausibility and whether there are more events than you would expect without vaccination. We refer to the number of events observed after vaccination as O, and the number you would expect in that population without vaccination, as E (Observed and Expected). If the ratio – O/E – is not greater than 1, then the vaccine is not likely to be the cause of the events.

“Authorities in various countries have carefully considered the evidence, and concluded that there is no excess of clotting events in people who have been vaccinated – even with the increased awareness of the possibility of such events (and the increased likelihood of reporting them if they should occur that inevitably follows such increases in awareness.)

“It is most regrettable that countries have stopped vaccination on such “precautionary” grounds: it risks doing real harm to the goal of vaccinating enough people to slow the spread of the virus, and to end the pandemic.”

 

Prof Stephen Evans, Professor of Pharmacoepidemiology, London School of Hygiene & Tropical Medicine, said:

“It would seem the move has been done following reports of serious blood clotting events in adults in Norway.

“These events were said by the Norwegian Institute responsible for delivering vaccines to be “they have had a reduced number of blood platelets. Blood clots and subsequent brain haemorrhages are a rare condition.”

“However, what these authorities do not make clear is that these coagulation disorders are very common in patients with Covid-19. Unless we are sure that those who suffered these unfortunate events very definitely did not have COVID-19 then it would seem to be premature to suggest it was the vaccine that caused these events.

“It has been well known for over a year that coagulation disorders, both clotting causing strokes, and bleeding (thrombocytopenia, which is a reduced number of platelets in the blood), are very common in patients with COVID-19.  Early reports from China noted over 30% of patients reaching hospital had thrombocytopenia.

“It is also a principle of regulatory action that when action is taken in regard to a particular product, that the alternatives definitely do not have the same problem. There was a case of thrombocytopenia in the US trial for the Pfizer vaccine, but detailed investigation made it clear that the vaccine was not the cause. The publicly available information on the AstraZeneca vaccine lists a total of 35 cases of thrombocytopenia reported on “Yellow Cards” in the UK up to 8th March 2021. This is a very small proportion of the yellow card reports which total over 54,000 in the context of nearly 10 million vaccinations delivered. For the Pfizer vaccine there are a total of 22 reports of thrombocytopenia out of 33,000 reports and well over 10 million vaccination doses. It is clear that the proportion of reports for this bleeding disorder is not different in the two vaccines.

“Covid definitely causes coagulation disorders and each of the vaccines prevents Covid disease, including more severe cases. Therefore, it is extremely likely that the benefit of the vaccine notably outweighs any risk for coagulation disorders and the vaccine prevents other consequences of Covid including deaths from other causes.

“It is entirely reasonable that detailed studies are done on the vaccines in regard to coagulation disorders, but it seems a step too far in taking precautions that would stop people getting vaccines that would prevent disease.”

 

Prof Adam Finn, Professor of Paediatrics, University of Bristol, said:

“Given the clear evidence we now have of real-world effectiveness of this vaccine against severe COVID-19 and against SARS CoV2 infection and the continuing widespread circulation of the virus in most if not all European countries, the potential public health consequences, both direct and reputational, of taking a stop-start approach need to be considered very carefully. In order to use vaccines effectively to help gain control over the pandemic there needs to be vaccine supply, vaccine delivery and vaccine acceptance. Getting all three lined up and in place at the same time is not easy and cannot be taken for granted while the need for rapid progress is obvious. If clear evidence of serious or life threatening side-effects emerges that will have important consequences. However so far it hasn’t and it’s highly undesirable to disrupt a complex and urgent programme every time people develop illnesses after receiving vaccine that may be coincidental and not causally related. Making the right call in situations like this is not easy but having a steady hand on the tiller is probably what is needed most.”

eg. https://www.bbc.co.uk/news/world-europe-56391818

Declared interests

Dr Peter English: “No interests.”

Prof Stephen Evans: “No conflicts of interest.  I am funded (one day per week) by LSHTM.  They get funding from various companies, including Astra Zeneca and GSK but I am not funded by them, I have no involvement in obtaining funding from them and I am not an investigator on any grants obtained from them.  I am the statistician to the ‘meta-Data Safety and Monitoring Board’ for CEPI.  I am paid for my attendance at those meetings and will be paid expenses for travel if that occurs.  I am a participant in the Oxford/Astra Zeneca trial, and on 13th January 2021 learnt I had received the active vaccine.”

Prof Adam Finn: “AF is an investigator in clinical trials of the Oxford AZ vaccine and other COVID-19 vaccines.  He is a member of JCVI, member of WHO SAGE working group on COVID-19 vaccines and chair of the WHO Euro technical advisory group of experts on immunization.”



Related Video: WHO assessing AstraZeneca vaccine

AstraZeneca vaccine rollout suspended after blood clot reports, Ireland’s medical chief
says

Irish Department of Health says programme ‘temporarily deferred’ while European Medicines Agency investigates


“Since we know with great certainty that the vaccine prevents Covid-19 with its attendant disease, and we are almost totally uncertain that the vaccine can have caused this problem, the risk and benefit balance is still very much in favour of the vaccine ...”

Tom Batchelor@_tombatchelor
3/14/2021

The rollout of the AstraZeneca Covid vaccine has been suspended in the Republic of Ireland following a recommendation by Irish health officials after reports of blood-clotting incidents elsewhere in Europe.

Serious blood-clotting events have been recorded after inoculations in Norway, where the AstraZeneca vaccine programme has been paused. Denmark and Iceland have also suspended the rollout pending an investigation.

In an email to The Independent, a spokesperson for the Irish Department of Health said administration of the AstraZeneca jab had been “temporarily deferred” as of Sunday morning.

“The European Medicines Agency (EMA) is already investigating a number of reports of thromboembolic (blood-clotting) events following vaccination with Covid-19 vaccine AstraZeneca,” the spokesperson added. “Further information is expected from the EMA in the next few days, which will include a review of these additional events.

Ireland’s Health Service Executive (HSE) also confirmed it would not be further administering the AstraZeneca vaccine until advised to do so. Other vaccinations are unaffected.



The decision came after Ireland’s National Immunisation Advisory Committee (NIAC) said the rollout should be paused.

Ireland’s deputy chief medical officer, Dr Ronan Glynn, said: “This recommendation has been made following a report from the Norwegian Medicines Agency of four new reports of serious blood-clotting events in adults after vaccination with Covid-19 vaccine AstraZeneca.

“It has not been concluded that there is any link between Covid-19 vaccine AstraZeneca and these cases.

“However, acting on the precautionary principle, and pending receipt of further information, the National Immunisation Advisory Committee has recommended the temporary deferral of the Covid-19 vaccine AstraZeneca vaccination programme in Ireland.”


A vaccinator in Dublin prepares a dose of the AstraZeneca jab
(Reuters)

Professor Karina Butler, chair of the NIAC, called it a “precautionary move” and said Irish health authorities would “continue to monitor the situation and if we can be satisfied that these events are coincidental and not caused by this vaccine we will reassess the situation”.
Top Articles

She added: “This vaccine is proven to be very effective against severe Covid-19 disease, which is associated with a risk of clotting events. We have taken this step out of an abundance of caution.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) said it was “aware” of the action in Ireland.

“We are closely reviewing reports but, given the large number of doses administered and the frequency at which blood clots can occur naturally, the evidence available does not suggest the vaccine is the cause,” the body added.

Dr Phil Bryan, its vaccines safety lead, said people "should still go and get their Covid-19 vaccine when asked to do so".

Meanwhile, Ireland’s Health Products Regulatory Authority (HPRA) said it had received a small number of reports associated with blood clots following vaccination with the AstraZeneca vaccine.

They were not as serious as those described in Norway and the number involved was extremely low.

A spokesperson for AstraZeneca said: “An analysis of our safety data that covers reported cases from more than 17 million doses of vaccine administered has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia with Covid-19 vaccine AstraZeneca.

“In fact, the reported numbers of these types of events for Covid-19 vaccine AstraZeneca are not greater than the number that would have occurred naturally in the unvaccinated population.

“In clinical trials, no trends or patterns were observed with regard to pulmonary embolism, deep vein thrombosis, or events possibly related to thrombocytopenia.

“A careful review of all available safety data including these events is ongoing and AstraZeneca is committed to sharing information without delay.”

The recommendation comes after Irish authorities had been pressing the pharmaceutical firm to speed up its supplies to the Republic. More than 117,000 AstraZeneca doses have been administered so far in Ireland.

The EMA reported that one person in Austria was diagnosed with blood clots and died 10 days after vaccination, but it stressed there is “currently no indication that vaccination has caused these conditions”.

Italy has followed Austria, Estonia, Latvia, Luxembourg and Lithuania in banning jabs from one particular batch of 1 million AstraZeneca vaccines, which was sent to 17 countries, after reports of a death.

Later on Sunday, the Netherlands also suspended its AstraZeneca rollout. The Dutch government said in a statement the vaccine will not be used until at least 29 March and it was reported that health authorities would be forced to cancel more than 40,000 appointments.

Another person was admitted to hospital in Austria with pulmonary embolism (blockage in arteries in the lungs) after being vaccinated, while one death involving a blood clot was reported in Denmark.

SPECULATION NOT FACT

A 50-year-old man is also thought to have died in Italy from deep vein thrombosis (DVT), while there has been an unconfirmed report of another death in Italy.

Commenting on the decision to pause the AstraZeneca rollout in Denmark and Norway, Stephen Evans, a professor at the London School of Hygiene and Tropical Medicine, said earlier this week that it was a “super-cautious approach based on some isolated reports in Europe”.


He added: “Since we know with great certainty that the vaccine prevents Covid-19 with its attendant disease, and we are almost totally uncertain that the vaccine can have caused this problem, the risk and benefit balance is still very much in favour of the vaccine in my view.


PRESS RELEASE


Our therapy areas
Our company
Careers
Investors
Media
Sustainability
Partnering

Update on the safety of COVID-19 Vaccine AstraZeneca

PUBLISHED 14 March 2021

Following a recent concern raised around thrombotic events, AstraZeneca would like to offer its reassurance on the safety of its COVID-19 vaccine based on clear scientific evidence. Safety is of paramount importance and the Company is continually monitoring the safety of its vaccine.

A careful review of all available safety data of more than 17 million people vaccinated in the European Union (EU) and UK with COVID-19 Vaccine AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia, in any defined age group, gender, batch or in any particular country.

So far across the EU and UK, there have been 15 events of DVT and 22 events of pulmonary embolism reported among those given the vaccine, based on the number of cases the Company has received as of 8 March. This is much lower than would be expected to occur naturally in a general population of this size and is similar across other licensed COVID-19 vaccines. The monthly safety report will be made public on the European Medicines Agency website in the following week, in line with exceptional transparency measures for COVID-19.

Furthermore, in clinical trials, even though the number of thrombotic events was small, these were lower in the vaccinated group. There has also been no evidence of increased bleeding in over 60,000 participants enrolled.

Ann Taylor, Chief Medical Officer, said: “Around 17 million people in the EU and UK have now received our vaccine, and the number of cases of blood clots reported in this group is lower than the hundreds of cases that would be expected among the general population. The nature of the pandemic has led to increased attention in individual cases and we are going beyond the standard practices for safety monitoring of licensed medicines in reporting vaccine events, to ensure public safety.”

In terms of quality, there are also no confirmed issues related to any batch of our vaccine used across Europe, or the rest of the world. Additional testing has, and is, being conducted by ourselves and independently by European health authorities and none of these re-tests have shown cause for concern. During the production of the vaccine more than 60 quality tests are conducted by AstraZeneca, its partners and by more than 20 independent testing laboratories. All tests need to meet stringent criteria for quality control and this data is submitted to regulators within each country or region for independent review before any batch can be released to countries.

The safety of the public will always come first. The Company is keeping this issue under close review but available evidence does not confirm that the vaccine is the cause. To overcome the pandemic, it is important that people get vaccinated when invited to do so.

COVID-19 Vaccine AstraZeneca, formerly AZD1222
COVID-19 Vaccine AstraZeneca was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

The vaccine has been granted a conditional marketing authorisation or emergency use in more than 70 countries across six continents, and with the recent Emergency Use Listing granted by the World Health Organization accelerates the pathway to access in up to 142 countries through the COVAX Facility.

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.


 Europe 02:49, 16-Mar-2021

Fear banning 'safe' AstraZeneca jab will set back Europe's COVID-19 fight
Thomas Wintle
CGTN
03:16

 

Experts have cautioned that while we shouldn't be "too worried" about taking the Oxford University-AstraZeneca vaccine, governments should be concerned that a ban on the jab may cause more long-term vaccine hesitancy. 

The warning comes as a slew of European countries, including Germany, the Netherlands and France, suspended the UK-made jab after reports the drug was linked to "serious blood clotting in adults." 

However, Lawrence Young, a professor of molecular oncology at Warwick University, told CGTN Europe that despite the reports, there was little to worry about: "I don't think any of us actually have any concerns that this is a dangerous vaccine." 

"We've seen all the data that's come out from the clinical trials that demonstrate this vaccine, along with others, is safe," he said, pointing to the fact the UK and the EU's regulators had already signed off on the jab. 

"It's inevitable that there are going to be some bumps in the road and, of course, one has to be always concerned about safety and monitoring safety," he said. But stressed: "I don't think we should be too worried." 

European nations initially started suspending single batches of the AstraZeneca vaccine in early March. However, after several reports of blood clotting and deaths in people who had taken the jab, some countries started enforcing a temporary ban.

More and more European countries are suspending the AstraZeneca COVID-19 vaccine after reports of unexpected possible side effects. /Joel Saget/AFP


But Young, an internationally renowned virus specialist who has recently been developing tests to detect COVID-19 antigens and antibodies, said it was vital to compare any adverse effects of vaccines with those that normally occur in the general population.

That was particularly true, he said, when blood clots were already a regular complication of COVID-19 and even prior to the pandemic, were "sadly, very, very common." 

"In the UK alone, there are at least 3,000 reported cases of blood clot-associated diseases a month," said the professor. "When you're vaccinating millions of people, you're going to see a similar trend in those individuals."

However, he expressed concern that the decision to suspend AstraZeneca could cause serious problems, given the fact that in Europe "there are many folk who are vaccine hesitant." 

He added: "I think it's really important that we report these differences, these adverse effects responsibly, but also stress the fact that overall, the safety data for this vaccine and the other vaccines are very, very good indeed."

Our current COVID-19 vaccines are "much safer than lots of over-the-counter drugs that people take every day," he added, saying that if AstraZeneca's bad PR didn't stop, it would negatively impact Europe's vaccine programs.    

"This is one of the front-runner vaccines, not least because it's cheap, and also we know it's very effective," said Lawrence.  

"We've heard a lot through the pandemic about 'none of us are safe until all of us are safe,'" he added in reference to the need for mass-vaccination.